Adma Biologics (ADMA) EBIAT (2016 - 2025)
Adma Biologics (ADMA) has disclosed EBIAT for 13 consecutive years, with $49.4 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT fell 55.87% year-over-year to $49.4 million, compared with a TTM value of $146.9 million through Dec 2025, down 25.67%, and an annual FY2025 reading of $146.9 million, down 25.67% over the prior year.
- EBIAT was $49.4 million for Q4 2025 at Adma Biologics, up from $36.4 million in the prior quarter.
- Across five years, EBIAT topped out at $111.9 million in Q4 2024 and bottomed at -$25.0 million in Q1 2022.
- Average EBIAT over 5 years is $8.9 million, with a median of -$6.6 million recorded in 2023.
- The sharpest move saw EBIAT soared 1299.42% in 2024, then crashed 55.87% in 2025.
- Year by year, EBIAT stood at -$16.6 million in 2021, then increased by 26.54% to -$12.2 million in 2022, then plummeted by 44.26% to -$17.6 million in 2023, then soared by 734.15% to $111.9 million in 2024, then plummeted by 55.87% to $49.4 million in 2025.
- Business Quant data shows EBIAT for ADMA at $49.4 million in Q4 2025, $36.4 million in Q3 2025, and $34.2 million in Q2 2025.